The Duke Translational Medicine Institute has been awarded a five-year grant of more than $47 million from the National Institutes of Health (NIH) to help speed biomedical research advances to patient care.
The Clinical and Translational Science Awards (CTSA) program, supported by the NIH’s National Center for Advancing Translational Sciences, provides infrastructure for researchers at Duke to conduct clinical trials, train young scientists and share developments across a consortium of more than 60 other leading centers throughout the country and beyond.
Four principal investigators will lead Duke’s CTSA program, including Robert Califf, MD, professor of medicine (Cardiology), director of the Duke Translational Medicine Institute and vice chancellor of Clinical and Translational Research; Monica Kraft, MD, chief of the Division of Pulmonary, Allergy and Critical Care Medicine; Jennifer Li, MD, MHS, chief of the Division of Pediatric Cardiology; and James McNamara, MD, director of the Center for Translational Neuroscience.
Among the CTSA leadership are faculty from the Department of Medicine: David Edelman, MD; Kimberley Johnson, MD; Scott Palmer, MD, MHS; Eric Peterson, MD, MPH; Kevin Schulman, MD, MBA; John Sundy, MD, PhD; Laura Svetkey, MD, MHS; and John Williams, MD.
Duke was one of the original 12 CTSA grant recipients in 2006, and the current award represents a renewal of that commitment. Funds pay for critical needs that form the foundation of biomedical research, including biostatistical and regulatory expertise, technical support, biobank access, startup capital and other essentials.
“Our vision is to create a research environment at Duke that links discovery science with a creative engine that can accelerate the development of new technologies based on scientific merit and societal need to improve public health through implementation of effective therapies,” Califf said. “With the renewal of the CTSA grant, we have the resources that can help us continue to realize that goal.”